 |
市场调查报告书
商品编码
1741115
凝血酶抑制剂市场：按类型、应用和地区划分Thrombin Inhibitor Market, By Type, By Application, By Geography |
||||||
价格
简介目录
凝血酶抑制剂市场规模预计在 2025 年为 346.8 亿美元，预计到 2032 年将达到 528.4 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 6.2%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 346.8亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期间：2025年至2032年的复合年增长率 | 6.20% | 2032年价值预测 | 528.4亿美元 |
凝血酶抑制剂是一类抗凝血剂（或一类具有抗凝血作用的药物），它们与凝血酶结合并抑制其活性，阻止血栓形成。它们用于预防动脉和静脉血栓症、预防和治疗深层静脉栓塞症，以及预防心房颤动引起的血栓性栓塞症。
使用凝血酶抑制剂治疗的疾病包括急性冠状动脉症候群、心臟血栓、肝素诱发的血小板减少性疾病(HIT)、静脉血栓栓塞症(VTE)、心房颤动 (Afib)、深层静脉栓塞症(DVT) 和肺动脉栓塞。
目前医疗保健专业人员使用的直接凝血酶抑制剂包括阿加曲班（静脉注射）、比伐卢定（静脉注射）和Dabigatran（锭剂）。
市场动态
深层静脉栓塞症(DVT)、肺动脉栓塞(PE) 和心房颤动 (AF) 的盛行率/发病率不断上升、对安全有效治疗的需求不断增加（由于全球人民的意识不断增强）、研发 (R&D) 不断增加以及新型抗凝血药物的推出是预期推动全球凝血酶抑制剂市场成长的关键因素。
例如，2018年6月，迈兰公司（Mylan NV）宣布在美国上市注射用比伐卢定（Bivalirudin for Injection），学名药。本产品为直接凝血酶抑制剂，采用250毫克单剂量管瓶，适用于患者抗凝血。在美国食品药物管理局（FDA）核准该产品的简化新药认证申请（ANDA）后，迈兰公司将向医院和医疗机构提供比伐卢定。
研究的主要特点
- 本报告对全球凝血酶抑制剂市场进行了详细分析，并介绍了预测期（2025-2032）的市场规模和复合年增长率。
- 它还强调了各个领域的潜在商机，并说明了该市场的引人注目的投资提案矩阵。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
- 该报告涵盖了全球凝血酶抑制剂市场的主要企业概况，基于以下参数，例如公司亮点、产品系列、关键亮点、性能和策略。
- 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
- 全球凝血酶抑制剂市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
- 相关人员将透过全球凝血酶抑制剂市场分析中使用的各种策略矩阵更轻鬆地做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- 一致的机会图（COM）
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 监管情景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
4. 凝血酶抑制剂市场-冠状病毒（COVID-19）大流行的影响
- COVID-19流行病学
- 供需侧分析
- 经济影响
5. 凝血酶抑制剂市场（按类型），2020 年至 2032 年
- 介绍
- 直接凝血酶抑制剂
- 间接凝血酶抑制剂
6. 凝血酶抑制剂市场（依应用划分），2020 年至 2032 年
- 介绍
- 深层静脉栓塞症（DVT）
- 肺动脉栓塞（PE）
- 心房颤动（AF）
- 其他（预防中风、急性冠状动脉症候群等）
7. 凝血酶抑制剂市场（依地区划分），2020 年至 2032 年
- 介绍
- 北美洲
- 美国
- 加拿大
- 欧洲
- 英国
- 德国
- 法国
- 义大利
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 东南亚国协
- 其他亚太地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 南非
- 北非
- 中部非洲
第八章 竞争态势
- Eisai Co., Ltd.
- Merck & Co., Inc.
- Novartis International AG
- GlaxoSmithKline plc
- AbbVie Inc.
- Portola Pharmaceuticals, Inc.
- CSL Behring
- Johnson & Johnson
- Sanofi SA
- Bayer AG
- Pfizer Inc.
- Bristol Myers Squibb
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company
- Aspen Pharmacare Holdings Limited
第九章 章节
- 调查方法
- 关于出版商
简介目录
Product Code: CMI5835
Thrombin Inhibitor Market is estimated to be valued at USD 34.68 Bn in 2025 and is expected to reach USD 52.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 34.68 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.20% | 2032 Value Projection: | USD 52.84 Bn |
Thrombin inhibitors are anticoagulants (or are a class of medication that act as anticoagulants) that bind to and inhibit the activity of thrombin, and therefore prevent blood clot formation. They are used to prevent arterial and venous thrombosis, as well as prevent and treat deep vein thrombosis and as prophylaxis in atrial fibrillation to avoid thromboembolism.
The conditions treated with thrombin inhibitors are; Acute Coronary Syndrome, Blood clots in heart, Heparin-induced thrombocytopenia (HIT), Venous thromboembolism (VTE), Atrial Fibrillation (Afib), Deep vein thrombosis (DVT), Pulmonary Embolism.
Direct thrombin inhibitor drugs that healthcare providers currently use include; Argatroban (IV injection), Bivalirudin (IV injection), Dabigatran (pill form).
Market Dynamics:
The increasing prevalence/incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF), a rise in demand for safe and effective treatment (due to increasing awareness among people worldwide), increase in research and development (R&D), and introduction of novel anticoagulants are major factors expected to propel the growth of the global thrombin inhibitor market.
For instance, in June 2018, Mylan N.V. announced the U.S. launch of Bivalirudin for Injection, a generic version of Angiomax. The product, 250 mg single-dose vial, is a direct thrombin inhibitor indicated for use as an anticoagulant in patients. Mylan is offering Bivalirudin to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).
Key features of the study:
- This report provides an in-depth analysis of the global thrombin inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2025-2032)
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global thrombin inhibitor market based on the following parameters such as company highlights, product portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, GlaxoSmithKline plc, AbbVie Inc., Portola Pharmaceuticals, Inc., CSL Behring, Johnson & Johnson, Sanofi S.A., Bayer AG, Pfizer Inc., Bristol Myers Squibb, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, and Aspen Pharmacare Holdings Limited, among others
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global thrombin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global thrombin inhibitor market
Detailed Segmentation:
- By Type:
- Direct Thrombin Inhibitors
- Indirect Thrombin Inhibitors
- By Application:
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Atrial Fibrillation (AF)
- Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Eisai Co., Ltd.
- Merck & Co., Inc.
- Novartis International AG
- GlaxoSmithKline plc
- AbbVie Inc.
- Portola Pharmaceuticals, Inc.
- CSL Behring
- Johnson & Johnson
- Sanofi S.A.
- Bayer AG
- Pfizer Inc.
- Bristol Myers Squibb
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company
- Aspen Pharmacare Holdings Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Thrombin Inhibitor, By Type
- Market Thrombin Inhibitor, By Application
- Market Thrombin Inhibitor, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Thrombin Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Thrombin Inhibitor Market, By Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Direct Thrombin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Indirect Thrombin Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Thrombin Inhibitor Market, By Application, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Deep Vein Thrombosis (DVT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Pulmonary Embolism (PE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Atrial Fibrillation (AF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others (Stroke Prevention, Acute Coronary Syndrome, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Thrombin Inhibitor Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Portola Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aspen Pharmacare Holdings Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
9. Section
- Research Methodology
- About us
02-2729-4219
+886-2-2729-4219
PCSK9 抑制剂市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测
KRAS抑制剂的全球市场:药物销售额，专利，价格，临床试验趋势(2030年)VISTA抑制剂的全球市场:临床试验，医药品开发机会，专利的洞察(2025年)
Hedgehog 通路抑制剂市场 - 全球产业规模、份额、趋势、机会和预测，按仿製药、按剂量、按最终用户、按地区和竞争进行细分，2020-2030 年预测CGRP 抑制剂市场 - 全球产业规模、份额、趋势、机会和预测，按治疗、给药途径、最终用户、地区和竞争进行细分，2020-2030 年预测克拉维酸系列 API 市场 - 全球产业规模、份额、趋势、机会和预测，按类型、应用、地区和竞争细分，2020-2030 年预测Xa 因子抑制剂市场 - 全球产业规模、份额、趋势、机会和预测，按药物类型、给药途径、应用、地区和竞争细分，2020-2030 年预测STAT3抑制剂的全球市场:市场机会与临床试验相关洞察(2028年)CGRP抑制剂的全球市场 - 全球产业分析，规模，占有率，成长，趋势，预测(2032年)
法屈唑市场：按适应症、最终用户划分 - 全球预测 2025-2030
▼